Aerska Secures $21M for Brain Disease Gene Silencing Tech
Aerska, a biotech startup focusing on brain diseases, has secured $21m (€17.8m) in seed financing. The company's experienced management team, led by former Ochre Bio CEO Jack O'Meara, was a key factor in attracting investment.
Aerska is developing a platform using 'brain shuttles' to deliver and silence harmful genes in the nervous system. This innovative approach aims to overcome the challenge of the blood-brain barrier, which has hindered the delivery of genetic medicines to the brain.
The funding round was co-led by Age1, Backed VC, and Speedinvest, with support from other investors. The funds will support Aerska's work on next-generation RNAi medicines for brain diseases like Alzheimer's and Parkinson's. Alzheimer's, a common form of dementia, contributes to 60-70% of cases, with 50 million people suffering from dementia worldwide in 2020, expected to reach 150 million by 2050.
Aerska's CEO and co-founder, Jack O'Meara, aims to enable precise and durable gene silencing in the nervous system. With the successful seed financing, the company is well-positioned to advance its innovative treatments for neurological diseases, offering hope to millions affected by conditions like Alzheimer's and Parkinson's.
Read also:
- New Immigration Law Guide: Practical Advice for Legal Professionals
- Willich's Senior Citizens Prepare for Council Elections, City Celebrates International Day of Older Persons
- Chronic Stress: Holistic Management for Physical and Mental Health
- St. John's Hospital in Pay Dispute Over CEO's Salary Increase
